Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.1352W HIGH $20.56
Volume
872.67 K
Value Traded
3.28 M
Short % Float
15.89%
-8.03%Week
-34.71%1 Month
-40.49%3 Month
-47.15%6 Month
-77.88%5 Year
-87.39%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
100.45 M
EPS (TTM)
-5.27
P/E Ratio
-
Ent. Value
-17.49 M
Total Shares
18.67 M
Float Shares
17.36 M
Insiders
10.22%
Institutions
73.00%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CRBP Catalyst Timeline
Dated clinical, regulatory and corporate events for Corbus Pharmaceuticals Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Corbus Pharmaceuticals Holdings, Inc.
776Total events
8Upcoming
95Tier-1 (high impact)
2014 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedCRB-701Trial
First patient dosed in TEMPO-1 registrational study of CRB-701 in 2L+ OPSCC
oropharyngeal squamous cell carcinoma (OPSCC)source ↗
▲Topline ReadoutCRB-913Clinical Data
CANYON-1 Phase 1b topline data announced: 5% mean weight loss at 60 mg at 12 weeks
obesitysource ↗
●R&D DayCRB-913Presentation
Corbus conference call webcast to discuss CANYON-1 topline data and CRB-913 potential in obesity
obesitysource ↗
▲Primary Endpoint MetCRB-913Clinical Data
CRB-913 met primary endpoint with statistically significant weight loss at all doses (p<0.0001 vs placebo)
obesitysource ↗
▲Safety Data UpdateCRB-913Clinical Data
CRB-913 generally well tolerated with psychiatric AEs in line with GLP-1s and favorable emerging GI profile
obesitysource ↗
▲IND ClearanceCRB-701IND
FDA clearance to proceed with TEMPO-1 registrational study
2L oropharyngeal cancersource ↗
▲IND ClearanceCRB-701IND
FDA clearance to initiate TEMPO-1 registrational study of CRB-701 in 2L OPSCC
2L oropharyngeal squamous cell carcinoma (OPSCC)source ↗
◆Management ChangeCorporate
Appointment of Leonardo Viana Nicacio, M.D. as Chief Medical Officer
◆Topline ReadoutCRB-913Clinical Data
Topline findings from CANYON-1 Phase 1b study of CRB-913 in obesity
obesitysource ↗
◆Trial InitiationCRB-701Trial
Initiation of TEMPO-1 registrational study of CRB-701 in 2L OPSCC
2L oropharyngeal squamous cell carcinoma (OPSCC)source ↗
◆Management ChangeCorporate
Dr. Dominic Smethurst to step down as Chief Medical Officer on June 30, 2026
●Oral PresentationCRB-701Presentation
Reported 2L+ monotherapy data at ASCO 2026
HNSCC and cervical cancerssource ↗
◆Trial InitiationCRB-701Trial
Initiate registrational study for CRB-701 in second-line HNSCC
head and neck squamous cell carcinomasource ↗
◆R&D DayCRB-701Presentation
KOL event at ASCO 2026 discussing CRB-701 HNSCC data
head and neck squamous cell carcinoma (HNSCC)source ↗
◆Topline ReadoutCRB-701Clinical Data
Monotherapy data expected mid-2026 with focus on durability and patient stratification
HNSCC, cervical cancersource ↗
◆Poster PresentationCRB-701Presentation
Poster presentation of CRB-701 Phase 1/2 data in HNSCC at ASCO 2026
head and neck squamous cell carcinoma (HNSCC)source ↗
◆Oral PresentationCRB-701Presentation
Oral presentation of CRB-701 Phase 1/2 data in cervical cancer at ASCO 2026
cervical cancersource ↗
◆Poster PresentationCRB-701Presentation
Poster presentation of updated data from Phase 1/2 study of CRB-701 in HNSCC at ASCO 2026
head and neck squamous cell carcinoma (HNSCC)source ↗
▲Full ResultsCRB-701Clinical Data
Updated Phase 1/2 data for CRB-701 in 2L OPSCC: confirmed ORR 42.9% at 3.6 mg/kg
Oropharyngeal squamous cell carcinoma (OPSCC)source ↗
◆AbstractCRB-701Presentation
Abstract #6062 available on ASCO website
head and neck squamous cell carcinomasource ↗
▲FDA Feedback ReceivedCRB-701FDA Meeting
Broad alignment with FDA on registration path for CRB-701 in HNSCC
head and neck squamous cell carcinoma (HNSCC)source ↗
▲FDA Feedback ReceivedCRB-701FDA Meeting
FDA alignment on registration path for CRB-701 in HNSCC and cervical cancer
head and neck squamous cell carcinoma (HNSCC) and cervical cancersource ↗
▲Enrollment CompleteCRB-913Trial
Completed enrollment and first visit in CANYON-1 study
obesitysource ↗
▲FDA Feedback ReceivedCRB-701FDA Meeting
Broad alignment with FDA on registration path for CRB-701 in HNSCC
head and neck squamous cell carcinoma (HNSCC)source ↗
▲Last Patient Last VisitCRB-913Trial
Last Patient First Visit in CANYON-1 Phase 1b study of CRB-913 for obesity
obesitysource ↗
▲FDA Feedback ReceivedCRB-701FDA Meeting
FDA alignment on registration path for CRB-701 in second-line HNSCC and cervical cancer
HNSCC; cervical cancersource ↗
◆Topline ReadoutCRB-913Clinical Data
12-week dose-range finding data in patients with obesity (n=240)
Obesitysource ↗
◆Trial InitiationCRB-701Trial
Registrational study TEMPO-1 of CRB-701 in 2L OPSCC to initiate in summer 2026
OPSCCsource ↗
●Management ChangeCorporate
Appointed new Chief Medical Officer, Chief Business Officer, and Board Member
◆FDA Feedback ReceivedCRB-701FDA Meeting
Update from FDA discussions regarding registrational study protocols expected Q1 2026
HNSCC, cervical cancersource ↗
◆Oral PresentationPresentation
CEO Yuval Cohen to participate in BMO 2026 Metabolic Health Summit panel
◆Oral PresentationPresentation
Corporate overview at 36th Annual Oppenheimer Healthcare Life Sciences Conference
◆Oral PresentationPresentation
Corporate overview at 44th Annual J.P. Morgan Healthcare Conference
◆Timing GuidanceCRB-701Presentation
Regulatory authority discussions and path to market update expected in Q1 2026
▲Oral PresentationCRB-701Presentation
Phase 1/2 CRB-701 data presented at 2026 ASCO Annual Meeting
oropharyngeal squamous cell carcinoma (OPSCC)source ↗
▲Topline ReadoutCRB-701Clinical Data
Phase 1/2 CRB-701 data in 2L+ OPSCC presented at ASCO 2026
oropharyngeal squamous cell carcinoma (OPSCC)source ↗
▲Fast Track DesignationCRB-701Designation
FDA granted Fast Track designation for CRB-701 in HNSCC
HNSCCsource ↗
Past FDA Catalysts and PDUFA Decisions
How CRBP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-14 | CRB-913 | Phase 1b topline data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C41 / 100
Pipeline Score
$69M
Pipeline Value
Overvalued
Valuation Signal
5
Drugs Scored
0.7x
rNPV / MCap
Top 37%
Micro Cap(rank 245 of 660)
Percentile Rank
Corbus Pharmaceuticals Holdings, Inc. carries a moderate pipeline score (41/100), with $832M risk-adjusted pipeline value, led by CRB-701 in Oropharyngeal Carcinoma (OPC) (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CRB-701 Small moleculeNCT07768189 | Oropharyngeal Carcinoma (OPC) | Phase 3 | RECRUITING | 260 | Mar 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every CRBP program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ben YongDirector | Sell | -2,000 9,383 held | $7.84 | 09/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CRBP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.3 % | 16.30 M | 1.74 M |
CRBP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CRBP ranks across every disease it competes in
Competitive Position is a premium feature
See how CRBP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCRBP News
CRBPCorbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
Corbus Pharmaceuticals has initiated the TEMPO-1 registrational study, dosing the first patient with CRB-701 for oropharyngeal squamous cell carcinoma (OPSCC). This study aims to evaluate CRB-701's efficacy against current standard treatments. The drug has shown promising results in earlier trials, and the FDA has granted it Fast Track designations for related cancers.
Read more →CRBPCorbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
Corbus Pharmaceuticals announced positive topline results from its CANYON-1 Phase 1b trial for CRB-913, an oral treatment for obesity. The study showed a mean weight loss of 5% at the 60 mg dose after 12 weeks, with no plateau in weight loss. CRB-913 demonstrated a favorable safety profile, suggesting its potential as a new class of obesity medication. The findings will be presented at ObesityWeek 2026.
Read more →CRBPCorbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
Corbus Pharmaceuticals will host a conference call on September 14 to discuss topline data from the CANYON-1 clinical trial of CRB-913, a new treatment for obesity. The Phase 1b study involves 240 participants and aims to evaluate the efficacy of CRB-913, a peripherally restricted oral CB1 inverse agonist. Dr. Harold Bays will be a guest speaker during the call.
Read more →CRBPCorbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Corbus Pharmaceuticals announced the grant of inducement equity awards to Leonardo Nicacio, who has joined as Chief Medical Officer. The grants include stock options and restricted stock units, aimed at incentivizing his employment. This decision aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting skilled professionals.
Read more →CRBPCorbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals reported its Q2 2026 financial results, highlighting FDA clearance for the TEMPO-1 study of CRB-701 in oropharyngeal cancer, with enrollment set to begin in September 2026. The company also concluded the CANYON-1 Phase 1b study of CRB-913 for obesity, expecting data release in the same month. Additionally, Corbus announced key leadership appointments to enhance its strategic direction.
Read more →CRBP▲ +5.4%on this newsshared move
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
Corbus Pharmaceuticals has announced the completion of the last patient visit in its CANYON-1 Phase 1b trial for CRB-913, an oral CB1 inverse agonist aimed at treating obesity. The trial, which involved 240 participants, is set to provide topline data in September 2026. CRB-913 has shown a favorable gastrointestinal profile and potential for effective weight management compared to existing therapies.
Read more →CRBPCorbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Corbus Pharmaceuticals has received FDA clearance to start the TEMPO-1 registrational study for CRB-701 in patients with second-line oropharyngeal squamous cell carcinoma. The study will evaluate CRB-701 against standard treatments and aims to support potential accelerated approval based on its efficacy. Approximately 14,000 patients are eligible for this treatment annually in the U.S.
Read more →CRBPCorbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
Corbus Pharmaceuticals has appointed Dr. Leonardo Viana Nicacio as Chief Medical Officer. Dr. Nicacio brings over 20 years of experience in oncology and drug development, notably in antibody drug conjugates. His appointment comes as Corbus prepares to initiate the TEMPO-1 study for CRB-701 in oropharyngeal squamous cell carcinoma, alongside other significant milestones in obesity treatment.
Read more →CRBP▼ -30.3%on this news
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
Corbus Pharmaceuticals announced promising results from its Phase 1/2 study of CRB-701, showing significant efficacy in treating second-line oropharyngeal and cervical cancers. The confirmed objective response rates were 42.9% for oropharyngeal squamous cell carcinoma and 34.4% for cervical cancer. The drug was well tolerated, with low rates of treatment discontinuation. A registrational study is set to begin in summer 2026.
Read more →CRBP▲ +18.3%on this newsshared move
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
Corbus Pharmaceuticals has appointed Nishant Saxena as Chief Business Officer and announced a conference call on May 26, 2026, to discuss updated data for its CRB-701 study. The data will be presented at the 2026 ASCO Annual Meeting, highlighting clinical responses in head and neck squamous cell carcinoma and cervical cancer. The company is advancing toward key milestones for its pipeline.
Read more →CRBPCorbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
Corbus Pharmaceuticals has appointed Brent Pfeiffenberger to its Board of Directors. Pfeiffenberger, an experienced pharma leader, is expected to enhance Corbus's strategic direction, particularly for its clinical programs CRB-701 and CRB-913. The company anticipates important data readouts this summer and has aligned with the FDA on the registration path for CRB-701.
Read more →CRBP▲ +6.3%on this newsshared move
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Corbus Pharmaceuticals Holdings, Inc. has announced its participation in upcoming investor conferences, including the RBC Capital Markets Global Healthcare Conference and the Jefferies Global Healthcare Conference. CEO Yuval Cohen will present a corporate overview and engage in one-on-one investor meetings at these events. The company continues to focus on developing therapies for oncology and obesity, showcasing its commitment to innovative solution development in these areas.
Read more →CRBPCorbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals reported its Q1 2026 financial results, highlighting significant progress in its oncology and obesity programs. The company has reached alignment with the FDA regarding the registration path for CRB-701 in treating head and neck squamous cell carcinoma and cervical cancer. Additionally, Corbus completed enrollment in the CANYON-1 study for CRB-913, with topline data expected this summer.
Read more →CRBPCorbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
Corbus Pharmaceuticals announced it will host a KOL event at the 2026 ASCO annual meeting to highlight new data from the Phase 1/2 clinical study of CRB-701. This study involves participants with head and neck squamous cell carcinoma and will be presented alongside subgroup analyses. The company recently aligned with the FDA regarding the registration path for CRB-701, indicating progress in its development. The event will feature insights from top oncology experts, facilitating a discussion on the findings.
Read more →CRBPCorbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
Corbus Pharmaceuticals announced that updated clinical data for CRB-701 will be presented at the ASCO 2026 Annual Meeting. The data includes findings from a Phase 1/2 study focusing on head and neck squamous cell carcinoma and cervical cancer. The company plans to initiate a registrational study for CRB-701 in mid-2026 and anticipates further data releases later in the year.
Read more →CRBPCorbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
Corbus Pharmaceuticals announced the enrollment of the last patient in the CANYON-1 Phase 1b clinical trial of CRB-913, an oral treatment for obesity. This 16-week study involves 240 participants and aims to explore dosing efficacy against obesity. Early Phase 1a results indicated nearly a 3% weight loss after 14 days, suggesting potential for CRB-913 as a new therapeutic option in obesity management. The company anticipates a successful data readout that may offer a promising alternative to existing treatments.
Read more →CRBPCorbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer FDA feedback enables Corbus to proceed with proposed registrational study design and end
Corbus Pharmaceuticals has announced significant progress in the development of its next-generation antibody drug conjugate, CRB-701, for treating head and neck squamous cell carcinoma (HNSCC) and cervical cancer. The FDA has provided feedback that allows Corbus to proceed with its proposed registrational study designs, which could potentially lead to accelerated approval. Additionally, updated monotherapy data is expected to be presented at the upcoming ASCO 2026 Annual Meeting. Notably, Chief Medical Officer Dr. Dominic Smethurst will be leaving the company by June 30, 2026.
Read more →CRBP▼ -6%on this news
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit
Corbus Pharmaceuticals Holdings Inc. announced its participation in the BMO 2026 Metabolic Health Summit, where CEO Yuval Cohen will discuss advancements in metabolic disease treatment. The company is developing CRB-913, an innovative drug for obesity that has shown potential in recent clinical trials. A Phase 1b study for CRB-913 is ongoing, with results expected by summer 2026. This engagement at the summit demonstrates Corbus's active role in addressing metabolic health challenges and their commitment to advancing their clinical pipeline.
Read more →CRBP▲ +19.2%on this news
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals reported its Q4 and 2025 financial results, highlighting promising data for CRB-701 in treating head and neck squamous cell carcinoma and cervical cancer. The company also noted significant weight loss results from CRB-913, an obesity treatment. Despite a net loss of $20.6 million, a recent public offering has extended its cash runway into 2028. Key data readouts for both programs are anticipated in mid-2026.
Read more →CRBPThis presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Refor
Corbus's presentation outlines forward-looking statements regarding their pipeline and clinical trials for therapeutic candidates CRB-701, CRB-913, and CRB-601. The company highlighted the upcoming key clinical readouts for 2026 and mentioned the FDA Fast Track Designation for CRB-701 in treating head and neck squamous cell carcinoma and cervical cancer. However, it cautioned that the predictions may be affected by various risks and uncertainties inherent in the biopharma industry. The efficacy and safety of CRB-701 relative to existing treatments such as PADCEV still require further validation through additional data.
Read more →About Corbus Pharmaceuticals Holdings, Inc.
Headquarters500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062
BIOPHARMAWATCH ELITE PLUS
Trade the next CRBP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime